P2 receptor antagonist PPADS confers neuroprotection against glutamate/NMDA toxicity.

Neurosci Lett

Department of Clinical Neurological Sciences, The No 252 Hospital of P.L.A., 81 Huayuan Street, Baoding City 071000, Hebei Province, PR China.

Published: March 2005

The present study investigated the role of pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid tetrasodium salt (PPADS), a P2 receptor antagonist, in protecting mouse cerebellar granule neurons (CGNs) against glutamate/NMDA-induced neuronal death. Neurotoxicity caused by 50 microM glutamate or 200 microM NMDA was significantly reduced in CGNs treated with PPADS. Such neuroprotection was in a time- and dose-dependent manner. The possibility that PPADS may block glutamate/NMDA-mediated intracellular Ca2+ influx to CGNs was investigated using temperature-controlled platereader measurements of fluorescence intensity of CGNs loaded with Ca2+-sensitive fluorescent dye Fluo-4AM. Interestingly, the rapid increase of calcium influx following glutamate/NMDA treatment was not significantly affected by prior treatment with PPADS. In contrast, MK801, a specific NMDA receptor antagonist, completely blocked intracellular Ca2+ influx. Taken together, these data suggest that inhibition of the P2 receptor may directly modulate NMDA receptor-mediated neurotoxicity through a Ca2+-independent mechanism.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neulet.2004.11.075DOI Listing

Publication Analysis

Top Keywords

receptor antagonist
12
intracellular ca2+
8
ca2+ influx
8
ppads
5
receptor
4
antagonist ppads
4
ppads confers
4
confers neuroprotection
4
neuroprotection glutamate/nmda
4
glutamate/nmda toxicity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!